Vonoprazan Dual or Triple Therapy Versus Bismuth‐Quadruple Therapy as First‐Line Therapy for Helicobacter pylori Infection: A Three‐Arm, Randomized Clinical Trial
Helicobacter · 2024
DOI: 10.1111/hel.13133 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Helicobacter, 2024. Verfasst von Ka Shing Cheung und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China. Hauptthemen laut MEDLINE: Helicobacter Infections, Sulfonamides, Drug Therapy, Combination, Helicobacter pylori. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: The Health Commission Grant of Guangdong Province, China, The Shenzhen Science and Technology Program.
Abstract (Originalsprache)
Background
We compared efficacy of vonoprazan‐dual or triple therapies and bismuth‐quadruple therapy for treatment‐naive Helicobacter pylori (HP) infection in Southern China, where primary resistance rates of clarithromycin and levofloxacin are >30%.
Methods
This was an investigator‐initiated, three‐arm, randomized clinical trial in Southern China. Between March 2022 and August 2023, treatment‐naïve HP‐infected adults were randomly assigned to receive one of three 14‐day regimens (1:1:1 ratio): vonoprazan‐dual (VA‐dual; vonoprazan 20 mg twice daily and amoxicillin 1 g thrice daily), vonoprazan‐triple (VAC‐triple; vonoprazan 20 mg/amoxicillin 1 g/clarithromycin 500 mg twice daily), or bismuth‐quadruple therapy containing bismuth, esomeprazole, tetracycline, and metronidazole. Primary outcome was noninferiority in HP eradication, evaluated by UBT 4–6 weeks post‐treatment by intention‐to‐treat (ITT) and per‐protocol (PP) analysis (based on subjects who completed 14‐day treatment and rechecked UBT). Bonferroni‐adjusted p ‐value of
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.
- Department of Medicine, School of Clinical Medicine, The University of Hong Kong, Hong Kong.
- Department of Medicine, Yulin Traditional Chinese Medicine Hospital, Guangxi, China.
- School of Clinical Medicine, The University of Hong Kong, Hong Kong.
ORCID-Profile: Ka Shing Cheung, Ho Yu Ng
Förderung
- The Health Commission Grant of Guangdong Province, China
- The Shenzhen Science and Technology Program
Zitieren
APA
Cheung, K. S., Lyu, T., Deng, Z., Han, S., Ni, L., Wu, J., Tan, J. T., Qin, J., Ng, H. Y., Leung, W. K., & Seto, W. K. (2024). Vonoprazan Dual or Triple Therapy Versus Bismuth‐Quadruple Therapy as First‐Line Therapy for Helicobacter pylori Infection: A Three‐Arm, Randomized Clinical Trial. Helicobacter. https://doi.org/10.1111/hel.13133
Vancouver
Cheung KS, Lyu T, Deng Z, Han S, Ni L, Wu J, et al. Vonoprazan Dual or Triple Therapy Versus Bismuth‐Quadruple Therapy as First‐Line Therapy for Helicobacter pylori Infection: A Three‐Arm, Randomized Clinical Trial. Helicobacter. 2024. doi:10.1111/hel.13133
BibTeX
@article{Cheung2024,
author = {Cheung, Ka Shing and Lyu, Tao and Deng, Zijie and Han, Shaowei and Ni, Li and Wu, Juan and Tan, Jing Tong and Qin, Jian and Ng, Ho Yu and Leung, Wai K and Seto, Wai-Kay},
title = {Vonoprazan Dual or Triple Therapy Versus Bismuth‐Quadruple Therapy as First‐Line Therapy for Helicobacter pylori Infection: A Three‐Arm, Randomized Clinical Trial},
journal = {Helicobacter},
year = {2024},
doi = {10.1111/hel.13133}
}
EUVIMED